Pharma — Januar 2023
-
2 Healthcare Stocks That Could Make You Richer
https://www.proinvestor.com/investornyt/924488/2-healthcare-stocks-that-could-make-you-richer
-
Lundbeck får opprioteret Alzheimersmiddel i USA af FDA
-
Analytiker: Forlomme til Lundbeck hos FDA er positiv men ventet
https://www.proinvestor.com/investornyt/924580/analytiker-forlomme-til-lundbeck-hos-fda-er-positiv-men-ventet -
Teva Pharma Confirms Participation From 48 States On Opioids Settlement https://www.proinvestor.com/investornyt/924699/teva-pharma-confirms-participation-from-48-
-
Roche: European Commission Approves Xofluza For Children Aged One Year And Above https://www.proinvestor.com/investornyt/926184/roche-european-commission-approves-xofluza-for-children-aged-one-year-and-above
-
Kort video - Ambu ' Bavarian Nordic ' Hansa Biopharma ' Genmab ' Novo Nordisk ' Zealand Pharma ' Anavex
Helge Larsen gennemgår det sidste nye om virksomhederne inden for pharma og biotek ud fra den kvalificerede debat og chat på Proinvestor. https://www.proinvestor.com/boards/109502/
-
Kort video -Der har det sidste års tid været meget støj på aktiemarkederne med gisninger om, hvordan centralbankerne vil agere osv. Det har medvirket til et volatilt marked. Forude venter masser af regnskaber fra Q4 - og dét, sammen med guidings, er noget, Helge Larsen og andre langsigtede investorer for alvor kan bruge til noget, når han ser fremad. https://www.proinvestor.com/boards/109501/
-
2 Healthcare Stocks You Can Buy and Hold for the Next Decade https://www.proinvestor.com/investornyt/929618/2-healthcare-stocks-you-can-buy-and-hold-for-the-next-decade
-
Lundbeck/Citi: Indledes med "neutral" og kursmål på 30 kr https://www.proinvestor.com/investornyt/930139/lundbeck-citi-indledes-med-neutral-og-kursmal-pa-30-kr
-
3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023 https://www.proinvestor.com/investornyt/931259/3-reasons-why-johnson-amp-johnson-stock-could-rebound-after-a-bad-start-in-2023
-
Lundbeck/Nordea: Kursmål sænkes før regnskab - stadig attraktiv aktie https://www.proinvestor.com/investornyt/933772/lundbeck-nordea-kursmal-saenkes-for-regnskab-stadig-attraktiv-aktie
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind